Disclaimer: On February 12, 2024 the FDA approved budesonide oral suspension (EOHILIA), a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with EoE.
Login to view comments.
Click here to Login
